These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2138904)

  • 1. Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZG, NSC 224070) during a phase I clinical trial.
    Betteridge RF; Bosanquet AG; Gilby ED
    Eur J Cancer; 1990 Feb; 26(2):107-12. PubMed ID: 2138904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone in plasma by solid-phase extraction and high-performance liquid chromatography.
    Betteridge RF; Bosanquet AG; Hunt P; Gilby ED
    J Chromatogr; 1988 Nov; 432():352-7. PubMed ID: 3220904
    [No Abstract]   [Full Text] [Related]  

  • 3. Stability of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ; NSC 224070) in aqueous solutions by high-performance liquid chromatography.
    Bosanquet AG; McLoughlin SB
    Invest New Drugs; 1985; 3(1):43-50. PubMed ID: 3838738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive anti-tumor agent RH1 in human and mouse plasma.
    Khan P; Abbas S; Hargreaves RH; Caffrey R; Megram V; McGown A
    J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):287-95. PubMed ID: 10410954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics.
    Bachur NR; Collins JM; Kelley JA; Van Echo DA; Kaplan RS; Whitacre M
    Clin Pharmacol Ther; 1982 May; 31(5):650-5. PubMed ID: 7075113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reduction of anti-tumour diaziridinyl benzoquinones.
    Butler J; Hoey BM; Lea JS
    Biochim Biophys Acta; 1987 Aug; 925(2):144-9. PubMed ID: 3040109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lack of correlation between toxicity and free radical formation of two diaziridinyl benzoquinones.
    Lea JS; Garner HJ; Butler J; Hoey BM; Ward TH
    Biochem Pharmacol; 1988 May; 37(10):2023-5. PubMed ID: 2837220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).
    Savaraj N; Lu K; Feun LG; Leavens ME; Stewart D; Burgess MA; Benjamin RS; Loo TL
    J Neurooncol; 1983; 1(1):15-9. PubMed ID: 6678302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas.
    Curt GA; Kelley JA; Kufta CV; Smith BH; Kornblith PL; Young RC; Collins JM
    Cancer Res; 1983 Dec; 43(12 Pt 1):6102-5. PubMed ID: 6640549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans.
    Schilsky RL; Kelley JA; Ihde DC; Howser DM; Cordes RS; Young RC
    Cancer Res; 1982 Apr; 42(4):1582-6. PubMed ID: 7060028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ability of a new antitumor agent, AZQ, to penetrate into cerebrospinal fluid.
    Gormley PE; Wood JH; Poplack DG
    Pharmacology; 1981; 22(3):196-8. PubMed ID: 7208602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.
    Feun LG; Savaraj N; Lu K; Guo Z; Raulston LG; Benjamin RS; Fields WS; Loo TL
    J Neurooncol; 1983; 1(3):219-24. PubMed ID: 6678971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of diaziquone (AZQ) plus GM-CSF.
    Hartmann LC; Ames MM; Reid JM; Richardson RL
    Invest New Drugs; 1995; 13(2):175-6. PubMed ID: 8617583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors.
    Feun LG; Yung WK; Leavens ME; Burgess MA; Obbens EA; Bedikian AY; Savaraj N; Stewart DJ; Benjamin RS; Fields WS
    J Neurooncol; 1984; 2(1):13-7. PubMed ID: 6088722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The alkylation of DNA in vitro by 2,5-bis(2-hydroxyethylamino)-3,6-diaziridinyl-1,4-benzoquinone (BZQ)--I.
    Butler J; Hoey BM; Ward TH
    Biochem Pharmacol; 1989 Mar; 38(6):923-7. PubMed ID: 2930592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of 2,5'-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (AZQ).
    Lu K; Savaraj N; Yap BS; Bedikian AY; Feun L; Benjamin RS; Loo TL
    Eur J Cancer Clin Oncol; 1983 May; 19(5):603-6. PubMed ID: 6683631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The murine disposition and pharmacokinetics of the antineoplastic agent, diaziquone (NSC 182986).
    Spiegel JF; Egorin MJ; Collins JM; Lerner BD; Bachur NR
    Drug Metab Dispos; 1983; 11(1):41-6. PubMed ID: 6132794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity.
    Gibson NW; Hartley JA; Butler J; Siegel D; Ross D
    Mol Pharmacol; 1992 Sep; 42(3):531-6. PubMed ID: 1406604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies.
    Berg SL; Balis FM; Zimm S; Murphy RF; Holcenberg J; Sato J; Reaman G; Steinherz P; Gillespie A; Doherty K
    J Clin Oncol; 1992 Jan; 10(1):143-8. PubMed ID: 1727916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alkylation of DNA by the new anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ).
    King CL; Wong SK; Loo TL
    Eur J Cancer Clin Oncol; 1984 Feb; 20(2):261-4. PubMed ID: 6538490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.